Bladder Cancer, Version 2.2016 Featured Updates to the NCCN Guidelines

Peter E. Clark, Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Jason A. Efstathiou, Thomas W. Flaig, Terence Friedlander, Richard E. Greenberg, Khurshid A. Guru, Noah Hahn, Harry W. Herr, Christopher Hoimes, Brant A. Inman, A. Karim Kader, Adam S. Kibel, Timothy M. Kuzel, Subodh M. Lele, Joshua J. MeeksJeff Michalski, Jeffrey S. Montgomery, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Daniel Petrylak, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Wade J. Sexton, Arlene O. Siefker-Radtke, Guru Sonpavde, Jonathan Tward, Geoffrey Wile, Mary A. Dwyer, Courtney Smith

Research output: Contribution to journalArticlepeer-review

68 Scopus citations

Abstract

These NCCN Guidelines Insights discuss the major recent updates to the NCCN Guidelines for Bladder Cancer based on the review of the evidence in conjunction with the expert opinion of the panel. Recent updates include (1) refining the recommendation of intravesical bacillus Calmette-Guérin, (2) strengthening the recommendations for perioperative systemic chemotherapy, and (3) incorporating immunotherapy into second-line therapy for locally advanced or metastatic disease. These NCCN Guidelines Insights further discuss factors that affect integration of these recommendations into clinical practice.

Original languageEnglish (US)
Pages (from-to)1213-1224
Number of pages12
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume14
Issue number10
DOIs
StatePublished - Oct 1 2016

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Bladder Cancer, Version 2.2016 Featured Updates to the NCCN Guidelines'. Together they form a unique fingerprint.

Cite this